Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy

• Main Authors: Barbara Ruaro (Author), Ilaria Gandin (Author), Riccardo Pozzan (Author), Stefano Tavano (Author), Chiara Bozzi (Author), Michael Hughes (Author), Metka Kodric (Author), Rossella Cifaldi (Author), Selene Lerda (Author), Marco Confalonieri (Author), Elisa Baratella (Author), Paola Confalonieri (Author), Francesco Salton (Author)
• Format: Book
• Published: MDPI AG, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of ~3 years. Nintedanib (NTD) has been shown to be useful in controlling interstitial lung disease (ILD) in IPF. Here we describe the experience of NTD use in IPF in a real-life setting. Objective. Our objective...